Hutchmed announced that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective allosteric inhibitor targeting Src homology-2 domain-containing protein tyrosine phosphatase-2, or SHP2. The first patient received their first dose on July 6, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
- HUTCHMED to Announce 2023 Half-Year Financial Results
- Hutchmed, Takeda publish phase 3 results of Fresco-2 trial in The Lancet
- HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
- Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
